The Liverpool human immunodeficiency virus (HIV) therapeutic drug monitoring (TDM) registry

The Liverpool human immunodeficiency virus (HIV) therapeutic drug monitoring (TDM) registry: studying influences upon plasma human immunodeficiency virus drug exposure

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN65117827

Enrollment

10000

Registered

2008-07-29

Start date

2005-10-01

Completion date

Unknown

Last updated

2021-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human immunodeficiency virus Infections and Infestations Unspecified human immunodeficiency virus disease

Interventions

The TDM registry is a registry of patients in whom therapeutic drug monitoring has been requested for HIV drugs. Data are kept anonymised, but linked to date of birth and hospital number.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Request for TDM of HIV drugs

Exclusion criteria

Exclusion criteria: Nil. Separate filters will be applied when analysing data, e.g. for children, pregnant women, patients on dialysis, patients receiving chemotherapy etc.

Design outcomes

Primary

Measure	Time frame
Correlation between drug exposure and: 1. Age, gender, weight, disease status, interacting medications, pregnancy etc. 2. Host genomic profile (genes implicated in HIV disease process and drug disposition)	—

Secondary

Measure	Time frame
No secondary outcome measures.	—

Countries

England, Ireland, Israel, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026